Home
Clinical Trials
Safety and Effectiveness of a...

Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients

Last Updated: 2005-06-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see if it is safe and effective to use IM862 to treat Kaposi's sarcoma (KS) in AIDS patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients are stratified by CD4 count, viral load, and prior systemic chemotherapy. Patients are randomized equally to receive either IM862 or placebo given intranasally every other day. Patients are seen every 4 weeks for 6 months or until disease progression to evaluate toxicity and efficacy. Quality of life is assessed before treatment, then every month for 6 months. At the end of the 6-month study evaluation period, patients with PR/CR (responders) remain on study and continue blinded treatment for an additional 6 months. For patients with stable disease (non-responders), the treatment assignment is unblinded and off-study IM862 compassionate use is offered for 6 months, regardless of treatment group. For patients with documented progressive disease (treatment failure), the treatment assignment is unblinded and off-study IM862 is offered for 6 months to any patient in the placebo group. For treatment failures in the IM862 group, IM862 is stopped and the patient is allowed other therapy options.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoma, Kaposi HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IM862

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients may be eligible for this study if they:

* Are HIV-positive.
* Have AIDS-related Kaposi's sarcoma.
* Have at least 5 skin or mouth sores that do not require chemotherapy.
* Have been taking anti-HIV drugs for at least 8 weeks before study entry with no changes in the regimen.
* Are at least 18 years old.
* Agree to practice effective methods of birth control.

Exclusion Criteria

Patients will not be eligible for this study if they:

* Have an AIDS-related opportunistic infection (except for genital herpes) within 2 weeks of study entry.
* Have had another type of cancer within the past 2 years (except for certain types of skin cancer, cervical cancer, or anal cancer).
* Have a severe chest cold.
* Have certain other serious medical conditions.
* Have received certain medications, including chemotherapy, within the past 4 weeks.
* Abuse alcohol or drugs.
* Are pregnant or breast-feeding.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Parkash Gill

Role: STUDY_CHAIR

David Scadden

Role: STUDY_CHAIR

Ariela Noy

Role: STUDY_CHAIR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.